Lyell Immunopharma Insider Trades
NASDAQ: LYELHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 4 · $75.00M
- Sales
- 29 · $612.75K
- Shares bought / sold
- 5.62M / 31.57K
- Net activity
- Net buying $74.4 million
Lyell Immunopharma insider activity
Over the last 12 months, Lyell Immunopharma insiders reported 41 transactions on SEC Form 4: 4 open-market purchases and 29 sales. Insiders bought $75.0 million and sold $612,747 worth of stock, for net insider buying of $74.4 million. The largest seller was Seely Lynn, with $355,124 in reported sales.
The most recent filing shows Lee Gary K. (Chief Scientific Officer) selling 129 shares at $15.93 on Nov 10, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put LYEL's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
LYEL insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Nov 10, 2026 | Bulis Veronica SanchezVP, Corporate Controller | Sale | 416 | $6.63K | Form 4 |
| Nov 10, 2026 | Seely LynnPresident and CEO | Sale | 545 | $8.68K | Form 4 |
| Nov 10, 2026 | Hill Stephen J.Chief Operating Officer | Sale | 88 | $1.40K | Form 4 |
| Nov 10, 2026 | Lee Gary K.Chief Scientific Officer | Sale | 129 | $2.05K | Form 4 |
| Nov 4, 2026 | ARCH Venture Partners IX, LLC & ARCH Venture Fund IX, L.P. & ARCH Venture Partners IX, L.P. & ARCH Venture Fund IX Overage, L.P. & ARCH Venture Partners IX Overage, L.P.10% Owner | Buy | 2,321,262 | $25.00M | Form 4 |
| Nov 4, 2026 | ARCH Venture Fund XIII, L.P. & ARCH Venture Partners XIII, L.P. & ARCH Venture Partners XIII, LLC & CRANDELL KEITH & GILLIS STEVEN & NELSEN ROBERT & Burow Kristina & BERNS PAUL L & BYBEE CLINTON10% Owner | Buy | 2,321,262 | $25.00M | Form 4 |
| Oct 12, 2026 | Aguirre Jarrad MattieuChief Medical Officer | Sale | 422 | $3.64K | Form 4 |
| Sep 10, 2026 | Shook DavidChief Medical Officer | Sale | 500 | $6.35K | Form 4 |
| Aug 21, 2026 | Lee Gary K.Chief Scientific Officer | Sale | 1,457 | $22.64K | Form 4 |
| Aug 21, 2026 | Hill Stephen J.Chief Operating Officer | Sale | 989 | $15.37K | Form 4 |
| Aug 21, 2026 | Seely LynnPresident and CEO | Sale | 9,589 | $149.01K | Form 4 |
| Aug 10, 2026 | Hill Stephen J.Chief Operating Officer | Sale | 89 | $1.28K | Form 4 |
| Aug 10, 2026 | Lee Gary K.Chief Scientific Officer | Sale | 131 | $1.88K | Form 4 |
| Aug 10, 2026 | Seely LynnPresident and CEO | Sale | 390 | $5.59K | Form 4 |
| Aug 10, 2026 | Bulis Veronica SanchezVP, Corporate Controller | Sale | 621 | $8.91K | Form 4 |
| Jul 27, 2026 | Innovative Cellular Therapeutics Holdings Ltd10% Owner | other | 38,500 | — | Form 4 |
| Jul 27, 2026 | Innovative Cellular Therapeutics Holdings Ltd10% Owner | other | 44,000 | — | Form 4 |
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd10% Owner | Sale | 10 | $137 | Form 4 |
| Jul 16, 2026 | Innovative Cellular Therapeutics Holdings Ltd10% Owner | Sale | 10 | $137.30 | Form 4 |
| Jun 29, 2026 | Innovative Cellular Therapeutics Holdings Ltd10% Owner | other | 76,000 | — | Form 4 |
| Jun 15, 2026 | Innovative Cellular Therapeutics Holdings Ltd10% Owner | other | 66,500 | — | Form 4 |
| Jun 10, 2026 | Shook DavidChief Medical Officer | Sale | 1,977 | $24.99K | Form 4 |
| May 11, 2026 | Lee Gary K.Chief Scientific Officer | Sale | 130 | $2.46K | Form 4 |
| May 11, 2026 | Seely LynnPresident and CEO | Sale | 388 | $7.34K | Form 4 |
| May 11, 2026 | Bulis Veronica SanchezVP, Corporate Controller | Sale | 217 | $4.10K | Form 4 |
| May 11, 2026 | Hill Stephen J.Chief Operating Officer | Sale | 89 | $1.68K | Form 4 |
| Mar 6, 2026 | ARCH Venture Fund XIII, L.P. & ARCH Venture Partners XIII, L.P. & ARCH Venture Partners XIII, LLC & CRANDELL KEITH & NELSEN ROBERT & Burow Kristina & GILLIS STEVEN & BERNS PAUL L & BYBEE CLINTON10% Owner | Buy | 488,090 | $12.50M | Form 4 |
| Mar 6, 2026 | ARCH Venture Partners IX, LLC & ARCH Venture Partners IX, L.P. & ARCH Venture Partners IX Overage, L.P. & ARCH Venture Fund IX, L.P. & ARCH Venture Fund IX Overage, L.P.10% Owner | Buy | 488,090 | $12.50M | Form 4 |
| Feb 11, 2026 | Lee Gary K.Chief Scientific Officer | Sale | 1,671 | $39.08K | Form 4 |
| Feb 11, 2026 | Seely LynnPresident and CEO | Sale | 7,455 | $174.37K | Form 4 |
| Feb 11, 2026 | Hill Stephen J.Chief Operating Officer | Sale | 1,236 | $28.91K | Form 4 |
| Feb 10, 2026 | Bulis Veronica SanchezVP, Corporate Controller | Sale | 254 | $5.87K | Form 4 |
| Feb 10, 2026 | Bulis Veronica SanchezVP, Corporate Controller | Award | 8,750 | — | Form 4 |
| Feb 10, 2026 | Lee Gary K.Chief Scientific Officer | Sale | 147 | $3.40K | Form 4 |
| Feb 10, 2026 | Hill Stephen J.Chief Operating Officer | Sale | 109 | $2.52K | Form 4 |
| Feb 10, 2026 | Seely LynnPresident and CEO | Sale | 438 | $10.13K | Form 4 |
| Feb 9, 2026 | Lee Gary K.Chief Scientific Officer | Award | 4,000 | — | Form 4 |
| Feb 9, 2026 | Hill Stephen J.Chief Operating Officer | Award | 4,000 | — | Form 4 |
| Feb 9, 2026 | Seely LynnPresident and CEO | Award | 20,000 | — | Form 4 |
| Dec 30, 2025 | Bulis Veronica SanchezVP, Corporate Controller | Sale | 936 | $30.25K | Form 4 |
| Dec 24, 2025 | Bulis Veronica SanchezVP, Corporate Controller | Sale | 1,136 | $43.93K | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4